| Identification | Back Directory | [Name]
Edotecarin | [CAS]
174402-32-5 | [Synonyms]
J 107088
PF 804950
Edotecarin
Edotecarin (J 107088)
5H-Indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione, 12-β-D-glucopyranosyl-12,13-dihydro-2,10-dihydroxy-6-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]- | [Molecular Formula]
C29H28N4O11 | [MDL Number]
MFCD00946605 | [MOL File]
174402-32-5.mol | [Molecular Weight]
608.55 |
| Chemical Properties | Back Directory | [Melting point ]
330° (dec) | [alpha ]
D23 +117° (c = 0.8 in 1:1 acetonitrile/water) | [Boiling point ]
1047.5±75.0 °C(Predicted) | [density ]
1.96±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
9.61±0.20(Predicted) | [color ]
Yellow to orange |
| Hazard Information | Back Directory | [Uses]
Treatment of cancer. | [in vivo]
Edotecarin produces an 83% increase in survival in mice bearing intracranial D-456MG glioma and shows a strong antimetastatic effect[1]. Edotecarin results in tumor growth delays ranging from 10.45 days at the lowest dose (3 mg/kg) to 24.83 days at the highest (100 mg/kg). Combination treatment of edotecarin plus irinotecan improves antitumor activity in vivo compared with either agent alone[2]. | [IC 50]
Topoisomerase I: 50 nM (IC50); Protein Kinase C: 160 μM (IC50) |
|
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
|